Consistent with on-target inhibition of LIMK1, Dabrafenib decreased p-cofilin levels in a dose-dependent manner, indicating that DAB reduces migration and invasion of GC cells through LIMK1-ADF/cofilin pathway. Here, CFL1 is linked to gastric cancer.